GE Healthcare Biacore 4000 molecular interaction analysis system
07 August, 2013 | Supplied by: Global Life Sciences SolutionsThe Biacore 4000 offers a complete solution for large-scale, label-free molecular interaction analysis, delivering high throughput without compromising on data quality.
GE Healthcare MicroCal iTC200 biomolecular interaction measurement system
07 August, 2013 | Supplied by: Global Life Sciences SolutionsThe MicroCal iTC200 allows direct and label-free measurement of binding affinity and thermodynamic parameters from biomolecular interactions. All binding parameters (affinity, stoichiometry, enthalpy and entropy) are available in a single experiment.
GE Healthcare Biacore T200 biomolecular interaction analysis system
06 August, 2013 | Supplied by: Global Life Sciences SolutionsThe Biacore T200 is a versatile, label-free system for detailed studies of biomolecular interactions, from early research to drug discovery and development and on to QC.
Why one person’s mutation kills when the same mutation in someone else is benign
02 August, 2013Scientists have begun to understand how the rest of the genome interacts with mutations, explaining why not everyone with identical genetic mutations develops a disease.
Bacteria invest in evolutionary success
02 August, 2013Researchers at Sydney and Exeter Universities have, for the first time, recreated and analysed the complex interplay between bacterial investment strategies and their outcomes.
GeneCopoeia Genome-TALER Human AAVS1 Safe Harbor Knock-in ORF Clones
31 July, 2013 | Supplied by: United Bioresearch Products Pty LtdGenome-TALER Human AAVS1 Safe Harbor Knock-in ORF Clones from GeneCopoeia are constructed for specifically transferring the ORF of interest from a donor plasmid into the AAVS1 safe harbour site in human chromosome 19 using the Genome-TALER Human AAVS1 Safe Harbor Gene Knock-in Kit.
Evolution is a group effort
29 July, 2013Researchers have found that rather than just one mutation causing enhanced survival, about five to seven mutations are required. These extra mutations are termed ‘genetic hitchhikers’ because they don’t appear to contribute to the enhanced fitness of the organism.
FDA permits marketing of TB bacteria and antibiotic-resistance test
26 July, 2013The US Food and Drug Administration (FDA) has authorised the marketing of the Xpert MTB/RIF assay, manufactured by Cepheid. This is the first FDA-reviewed test that can rapidly detect the bacteria that cause tuberculosis (TB) and determine if the bacteria contain genetic markers that make them resistant to rifampin, an important antibiotic for the treatment of TB.
Qiagen and Exosome Diagnostics partner to create biofluid sample preparation kits
24 July, 2013Qiagen and Exosome Diagnostics have announced a partnership to develop and commercialise high-performance kits for the capture and processing of RNA and DNA from biofluid exosomes and other microvesicles.
Now they tell us - high omega-3 fatty acids levels increase risk of prostate cancer
19 July, 2013Fatty acids derived from fatty fish and fish-oil supplements, usually lauded as ‘cure-alls’, have been found to increase the risk of developing aggressive prostate cancer.
Biobase ELISA microplate reader
17 July, 2013 | Supplied by: Crea Laboratory Technologies Pty LtdBiobase has produced the ELISA microplate reader, suitable for a wide range of uses in the fields of hospital clinical diagnosis, immune pathology testing, microbial antigen and antibody detection, parasitic diseases diagnosis, blood diseases diagnosis, endocrine disorder measure, plant diseases and insect pet studies.
Qiagen therascreen EGFR RGQ PCR Kit
15 July, 2013 | Supplied by: QIAGEN Pty LtdQiagen has received approval by the US FDA to market the therascreen EGFR test as a companion diagnostic to guide the use of Boehringer Ingelheim’s targeted therapy GILOTRIF (afatinib) for treatment of metastatic NSCLC in patients whose tumours have certain EGFR gene mutations.
Using sequencing to identify pathogens quickly
12 July, 2013A method has been developed that can rapidly identify pathogenic species and strains causing illnesses, such as pneumonia. This could help lead to earlier detection of disease outbreaks and pinpoint effective treatments more quickly.
Life Technologies Ion AmpliSeq Exome Kit
10 July, 2013 | Supplied by: Life TechnologiesLife Technologies’ Ion AmpliSeq Exome Kit delivers very good exome sequencing performance, with up to 98% of bases covered at 10x, and up to 96% of bases covered at 20x, for a single exome.
NZ/UK collaboration for rapid point-of-care diagnostics
09 July, 2013New Zealand biomarker research company BioTest Diagnostics is collaborating with UK diagnostics development company AgPlus to bring immediate point-of-care testing benefits to the veterinary market.
